fig1
![Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population](https://image.oaes.cc/01cdaed9-099e-4097-8ed1-d5d150158891/1503.fig.1.png)
Figure 1. (A) Probability of progression-free survival in all patients: 13.7 months (95% CI: 11.24-16.16 months); (B) probability of overall survival in all patients: 21.0 months (95% CI: 13.42-28.58 months). CI: confidence interval
Figure 1. (A) Probability of progression-free survival in all patients: 13.7 months (95% CI: 11.24-16.16 months); (B) probability of overall survival in all patients: 21.0 months (95% CI: 13.42-28.58 months). CI: confidence interval
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/